LYZ activates macrophages to kill tumors and plays a role in tumor suppression; however, under chronic inflammation, LYZ releases proinflammatory factors (IL-6, TNF-α) to promote immunosuppression in the tumor microenvironment. Here, TNF is linked to neoplasm.